Is Ideaya Biosciences Inc (IDYA) overvalued? · rev $7.0M
Ideaya Biosciences Inc (IDYA) is a biotechnology company listed on NASDAQ.
This page asks whether Ideaya Biosciences Inc (IDYA) looks expensive on cached numbers — not a short thesis.
Latest reported IDYA revenue for 2024-12-31 was $7.0M. Net income was -$274.5M. Revenue was down 70.1% from 2023-12-31 to 2024-12-31. IDYA currently screens at market cap $2.96B.
IDYA currently screens at market cap $2.96B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IDYA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IDYA stock page for the full model, not this heading.
Not investment advice.